{"id":29406,"date":"2025-08-28T21:07:12","date_gmt":"2025-08-28T21:07:12","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/29406\/"},"modified":"2025-08-28T21:07:12","modified_gmt":"2025-08-28T21:07:12","slug":"relay-therapeutics-to-participate-in-two-upcoming-investor","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/29406\/","title":{"rendered":"Relay Therapeutics to Participate in Two Upcoming Investor"},"content":{"rendered":"<p align=\"left\">CAMBRIDGE, Mass., Aug.  28, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GWvAhibyELWnNZnz0Fc4ttYYBKbSxytIbWsYae_UC0GKYoAA6gZ4WnbDrukfY_zOeAIgXAyamUsGfRlqBbgve_WvpzhWumhfZ76URG9aazA=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Relay Therapeutics, Inc.\">Relay Therapeutics, Inc.<\/a> (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:<\/p>\n<ul type=\"disc\">\n<li>2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 2:15 p.m. ET<\/li>\n<li>Morgan Stanley 23rd Annual Global Conference on Wednesday, September 10, 2025 at 11:30 a.m. ET<\/li>\n<\/ul>\n<p>The fireside chats will be webcast live and may be accessed through Relay Therapeutics\u2019 website under Events in the News &amp; Events section through the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KWe7J_CGG3dtT8FVFScP-XGefBjXqqCzP85czlVzE_DtjqbUoHSOMxuD1F60n7yhS89Mq-bCyWj6eoUgteD3-LJEsjlfgqHdn0sWHb7XT8TC-VvG85aYTiFx4EHpIxQTlkwvDSEBtrK5h_GbXOg7ThCRMmhoAhs8fh-mNRPKHCmAV0ldF7J87ovf0-g6bnBE\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/ir.relaytx.com\/news-events\/events-presentations<\/a>. An archived replay of the webcast will be available for up to 30 days following the event.<\/p>\n<p><strong>About Relay Therapeutics<\/strong><\/p>\n<p>Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing\u00a0potentially life-changing therapies for\u00a0patients living with cancer and genetic disease. Relay&#8217;s Dynamo\u00ae platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company\u2019s lead clinical asset,\u00a0RLY-2608, is the first pan-mutant selective PI3K\u03b1 inhibitor to enter clinical development and\u00a0is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+\/HER2- metastatic breast cancer. RLY-2608 is also being investigated in a group of genetic disease indications called PI3K\u03b1-driven vascular malformations. Relay&#8217;s\u00a0pipeline also includes late-stage research programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WYsx3OfSyqxRbn409MMuJqBPB_F_1o07Jtz56RP6L3VgwnPfgG3I-PsJKgDzDS3-llXiVMXkwD1WLor0IWgfQWz0y9mlmvzl3ML3MMowU8A=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.relaytx.com\">www.relaytx.com<\/a>\u00a0or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9SeR9XrXLfqdmL-wg4_pfK3sgvwaqCqE9FId5G6Di2se11SY2c45_mUafOPXZnoGGTjuK6pWWZiZ94nn2sevP8NXJqTAMa-GWgEtT-uoYP7df5o29FNUJIr6UbvA2ylLqOl21KWRT3u7_v1kF7iK18GDzANI_EuEvHuXXZ5-x2QJYZOhiQzkfprhb_ORvWGvrjeFch4VhwlrH82zbFxmdA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"follow us on LinkedIn\">follow us on LinkedIn<\/a>.<\/p>\n<p><strong>Contact:<\/strong><br \/>Pete Rahmer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7tSc-uGk6L75oHTcU49GMrU_UaYU4UeRv7EclkgSGJZRBF-SItFVSHxNsiiajkVC85-jX1JfdHx9qjuUhtc1mk6JpmQFc3nwGQ6w5BLlaRs=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"prahmer@relaytx.com\">prahmer@relaytx.com<\/a><\/p>\n<p><strong>Media:<\/strong><br \/>Dan Budwick<br \/>1AB<br \/>973-271-6085<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5-BZH2v1FuDgwi5vg6hK6z7p4dVg1IaLf6fri3QTF2DWeTVsGQtzPeBgtxFEVzRnBVw2qJaSZezsO3HSit1mpa9y1xUqMxxC6t-h570wBdg=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"dan@1abmedia.com\">dan@1abmedia.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/08\/Relay-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) &#8212; Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision&hellip;\n","protected":false},"author":2,"featured_media":29407,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[74],"tags":[18,19,1297,17,23433,23434,82],"class_list":{"0":"post-29406","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-technology","8":"tag-eire","9":"tag-ie","10":"tag-inc","11":"tag-ireland","12":"tag-nasdaqrlay","13":"tag-relay-therapeutics","14":"tag-technology"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/29406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=29406"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/29406\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/29407"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=29406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=29406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=29406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}